A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

NCT03405454 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Clear Cell Carcinoma

Interventions

DRUG: durvalumab
DRUG: standard chemotherapy

Sponsor

National University Hospital, Singapore